Treatment for Migraine and Mood

Launched by AMANDA SHALLCROSS · Oct 10, 2022

Keywords

ClinConnect Summary

This clinical trial is exploring how different methods of Mindfulness-Based Cognitive Therapy (MBCT) can help people who experience migraines and depressive symptoms. The study compares three ways to deliver MBCT: over the phone, through video, and an enhanced usual care approach. Researchers are looking for participants aged 18 and older who have been diagnosed with migraines and have experienced 4 to 14 headache days each month. Additionally, participants should have mild to moderate depressive symptoms, as indicated by their responses to a questionnaire.

If you decide to join the trial, you’ll be part of a study that aims to find out if these mindfulness techniques can improve your migraine symptoms and mood. You’ll need to keep a diary to track your headaches, and it's important that you have a stable medication routine during the study. The trial is currently recruiting participants, and it’s a great opportunity to contribute to research in this area while potentially finding relief from your symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Currently meets ICHD-3 (International Classification for Headache Disorders - 3rd Edition) criteria for migraine using the American Migraine Prevalence and Prevention Diagnostic Module
• • Self-reported 4-14 headache days per month, with at least one attack meeting migraine criteria
• • Score between 5-14 on the PHQ-9 (Patient Health Questionnaire)
• • Age ≥ 18
• • Ability to read and speak English
• • Capacity to consent
• • Prospective diary-confirmed 4-14 headache days per month, with at least one attack meeting migraine criteria
• • ≥1 year of migraine
• Exclusion Criteria:
• • Meeting ICHD-3 criteria for persistent headache attributed to traumatic injury to the head (post-traumatic headache) on the American Migraine Prevalence and Prevention Diagnostic Module
• • Changes in preventive migraine medication or anti-depressant medication within 6 weeks of intake
• • Changes in longer-term migraine prevention (onabotulinum toxin A, injectable or oral anti-calcitonin gene related peptide treatment; neuromodulatory device) within 3 months of intake
• • Changes in acute migraine treatment started within 4 weeks of enrollment
• • Comorbid psychiatric illness or clinical features that would interfere with participant's ability to participate in or receive benefit from the intervention, including but not limited to: active suicidal ideation; recent history of psychosis or mania; borderline, histrionic or narcissistic personality disorder; cognitive impairment; sensory disabilities; bipolar disorder; obsessive-compulsive disorder, drug use
• • Prior history of engaging in formal mindfulness-based interventions including: MBSR (Mindfulness-based stress reduction), MBCT (Mindfulness-based cognitive therapy), Acceptance and Commitment therapy, Dialectical Behavior Therapy
• • Current daily meditation practice
• • Inability to adhere to headache diary during baseline evaluation period (recorded fewer than 25/28 days)
• • Unwilling to maintain stable current acute or preventive medication dosages for study duration
• • Any condition that would prevent being a suitable candidate or interfere with medical care needs